Cystoscopy and Transurethral Resection of Bladder Tumor (TURBT) is a core procedure in urologic oncology that combines diagnostic endoscopy with minimally invasive surgical resection. The primary clinical objective is to visual inspect the mucosal lining of the urinary tract, excise all visible bladder tumors, and collect muscular tissue samples to determine the depth of tumor invasion.

The procedure works by accessing the bladder via the natural anatomical pathway of the urethra (the tube carrying urine out of the body), eliminating the need for external surgical incisions. A specialized endoscopic instrument called a resectoscope utilizes electrical current or laser energy to shave away tumor tissue layer by layer. The obtained tissue is submitted to a pathologist to evaluate cellular grading and muscle invasion, which directly dictates subsequent oncology treatment plans according to European Association of Urology (EAU) and American Urological Association (AUA) guidelines.

The patient is positioned in the dorsal lithotomy position under general or regional anesthesia. A rigid or flexible cystoscope is introduced into the urethra to perform a systematic visual examination of the urethral mucosa, prostate (in men), bladder trigone, ureteral orifices, and all bladder mucosal surfaces. Once the bladder lesion is identified, a resectoscope fitted with a tungsten wire loop is advanced. Monopolar or bipolar electrical current cuts through the tumor base and cauterizes underlying blood vessels. Resected tissue chips are flushed out of the bladder using an ellik evacuator or irrigation syringe. The detrusor muscle bed at the resection base is selectively electrocauterized to achieve complete hemostasis. Tissue specimens are placed in formalin and sent for histopathological analysis. An intravesical chemotherapy agent, such as mitomycin C or gemcitabine, may be instilled into the bladder for 60 minutes if clinically indicated. A Foley catheter is placed for temporary urinary drainage.

Cystoscopy combined with TURBT provides definitive evidence-based clinical benefits:

• Simultaneous Diagnosis and Therapy: Permits immediate surgical excision of visible tumors during the diagnostic evaluation without requiring open surgery.
• Accurate Pathological Staging: Obtains deep detrusor muscle tissue necessary to accurately distinguish between muscle-invasive and non-muscle-invasive disease, preventing understaging (EAU Guidelines 2023).
• Preservation of Native Bladder Function: Minimally invasive transurethral access avoids abdominal incisions, reduces postoperative pain, and preserves normal urinary storage and voiding mechanisms.
• Reduction in Recurrence Risk: Immediate post-TURBT intravesical instillation of chemotherapy reduces 5-year disease recurrence rates by up to 35% in low-to-intermediate risk cases (Sylvester et al., 2016).
• Rapid Recovery Profile: Most procedures are completed as day-case or overnight surgical stays, allowing patients to resume regular daily activities within one to two weeks.

Recovery following TURBT progresses through distinct short-term and long-term phases:

• First 24–48 Hours: Mild to moderate hematuria (blood in urine) and dysuria (burning sensation during urination) are expected. A urinary catheter may remain in place for 24 to 72 hours to prevent urinary retention and blood clot obstruction.
• Days 3–14: As the internal resected wound forms a scab and heals, mild urinary frequency and urgency persist. Small blood clots or scab fragments may pass in the urine around day 7 to 10 as the scab sloughs off.
• Weeks 2–4: Urinary symptoms typically resolve completely. Strenuous physical exercise, heavy lifting (>10 lbs), and sexual activity may be safely resumed once gross hematuria has resolved and medical clearance is granted.
• Surveillance Phase: Because bladder tumors exhibit high rates of recurrence (30%–70%), patients undergo structured cystoscopic follow-up at 3, 6, and 12 months, continuing annually based on initial pathological risk stratification (AUA/SUO Guidelines 2020).

Cystoscopy and TURBT are indicated for diagnosing and managing several conditions of the lower urinary tract:

• Non-Muscle-Invasive Bladder Cancer (NMIBC): Including Ta (papillary tumors confined to the mucosa), T1 (tumors invading the subepithelial connective tissue), and CIS (carcinoma in situ).
• Muscle-Invasive Bladder Cancer (MIBC) Staging: Providing definitive pathological confirmation of muscle wall invasion (stage T2 or higher) to guide radical surgical or multimodality therapy.
• Unexplained Hematuria: Investigating visible (gross) or non-visible (microscopic) blood in the urine when diagnostic imaging is inconclusive.
• Benign Bladder Lesions: Diagnosis and removal of non-cancerous growths such as papillomas, inverted papillomas, cystitis cystica, or urethral/bladder polyps.
• Bladder Pathologies: Evaluating persistent lower urinary tract symptoms, recurrent urinary tract infections, chronic bladder pain, or suspicious urine cytology.

Preoperative preparation includes full blood counts, metabolic panels, coagulation profiles, and urine culture to exclude active infection. Anticoagulant and antiplatelet medications (such as warfarin, aspirin, clopidogrel, or direct oral anticoagulants) must be held prior to surgery under specialist guidance. Patients fast from solid foods for 6 to 8 hours before anesthesia. Prophylactic intravenous antibiotics are administered immediately before the procedure to reduce infection risks according to AUA antimicrobial prophylaxis guidelines.

Common and mild side effects include transient gross hematuria, mild dysuria, urinary frequency, and bladder spasms. Less common complications (1%–5%) include urinary tract infection, prolonged bleeding requiring catheter re-insertion or bladder irrigation, and temporary urinary retention. Rare but serious complications (<1%) include deep bladder wall perforation into the intraperitoneal or extraperitoneal space, severe hemorrhage requiring blood transfusion or re-exploration, urethral stricture formation, bladder neck contracture, and anesthesia-related cardiovascular or respiratory events.

The patient clinical journey for cystoscopy and TURBT spans several key clinical phases:

• Pre-Procedure Evaluation: Diagnostic workup including urine cytology, radiological imaging (such as CT urography), blood tests, and an anesthesia fitness assessment. Discontinuation of blood-thinning medications is arranged under medical supervision.
• Surgical Intervention: Performed in an operating room under general or spinal anesthesia. The urologist performs a systematic diagnostic cystoscopy, followed by tumor resection using a resectoscope. Intravesical chemotherapy (such as mitomycin C) may be instilled into the bladder immediately post-resection.
• Immediate Recovery: A three-way continuous bladder irrigation catheter is typically placed to keep the bladder clear of blood clots. Patients are monitored in the recovery unit until urine color clears and spontaneous voiding is confirmed following catheter removal.
• Pathology and Staging: Within 7 to 14 days, tissue analysis provides definitive histological diagnosis, grade, and stage (T category).
• Long-Term Surveillance: Based on clinical risk stratification, patients enter a systematic surveillance schedule involving periodic flexible cystoscopy and urinary biomarkers to monitor for disease recurrence or progression.